AU2002230411A1 - 1-(2-m-methanesulfonamidophenylethyl)-4-(m-trifluoromethylphenyl)piperazine and pharmaceutically acceptable salts and solvates thereof and their use in the treatment of incontinence - Google Patents

1-(2-m-methanesulfonamidophenylethyl)-4-(m-trifluoromethylphenyl)piperazine and pharmaceutically acceptable salts and solvates thereof and their use in the treatment of incontinence

Info

Publication number
AU2002230411A1
AU2002230411A1 AU2002230411A AU3041102A AU2002230411A1 AU 2002230411 A1 AU2002230411 A1 AU 2002230411A1 AU 2002230411 A AU2002230411 A AU 2002230411A AU 3041102 A AU3041102 A AU 3041102A AU 2002230411 A1 AU2002230411 A1 AU 2002230411A1
Authority
AU
Australia
Prior art keywords
solvates
pharmaceutically acceptable
acceptable salts
incontinence
methanesulfonamidophenylethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002230411A
Inventor
John Mehnert Schaus
Dennis Charles Thompson
Karl Bruce Thor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2002230411A1 publication Critical patent/AU2002230411A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Abstract

The present invention provides a compound of the formula (I)and the pharmaceutically acceptable salts and solvates thereof, which is useful for treating bladder over-activity or urinary incontinence.
AU2002230411A 2000-11-29 2001-11-16 1-(2-m-methanesulfonamidophenylethyl)-4-(m-trifluoromethylphenyl)piperazine and pharmaceutically acceptable salts and solvates thereof and their use in the treatment of incontinence Abandoned AU2002230411A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25020300P 2000-11-29 2000-11-29
US60/250,203 2000-11-29
PCT/US2001/042949 WO2002044159A2 (en) 2000-11-29 2001-11-16 1-(2-m-methanesulfonamidophenylethyl)-4-(m-trifluoromethylphenyl)piperazine and pharmaceutically acceptable salts and solvates thereof and their use in the treatment of incontinence

Publications (1)

Publication Number Publication Date
AU2002230411A1 true AU2002230411A1 (en) 2002-06-11

Family

ID=22946725

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002230411A Abandoned AU2002230411A1 (en) 2000-11-29 2001-11-16 1-(2-m-methanesulfonamidophenylethyl)-4-(m-trifluoromethylphenyl)piperazine and pharmaceutically acceptable salts and solvates thereof and their use in the treatment of incontinence

Country Status (9)

Country Link
US (1) US6864262B2 (en)
EP (1) EP1341777B1 (en)
JP (1) JP2004517081A (en)
AT (1) ATE374192T1 (en)
AU (1) AU2002230411A1 (en)
CA (1) CA2427098A1 (en)
DE (1) DE60130677T2 (en)
ES (1) ES2292636T3 (en)
WO (1) WO2002044159A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012048710A1 (en) * 2010-10-15 2012-04-19 Concit Pharma Aps Combinations of serotonin receptor agonists for treatment of movement disorders
NZ700474A (en) 2012-04-18 2016-10-28 Contera Pharma Aps Orally available pharmaceutical formulation suitable for improved management of movement disorders

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1300728A (en) * 1959-10-20 1962-07-02
BE755015A (en) 1969-08-20 1971-02-01 Byk Gulden Lomberg Chem Fab PIPERAZINYL-ALCOYLAMINO-URACILS SUBSTITUTED BY AN ARYL GROUP, THEIR ETHERS AND THIOETHERS, AND THEIR PREPARATION PROCESS
BE759371A (en) 1969-11-24 1971-05-24 Bristol Myers Co HETEROCYCLICAL AZASPIRODECANEDIONES AND METHODS FOR THEIR PREPARATION
FR2362628A1 (en) 1976-08-26 1978-03-24 Roussel Uclaf NEW DERIVATIVES OF PIPERIDYL-INDOLE AND THEIR SALTS, METHOD OF PREPARATION AND APPLICATION AS MEDICINAL PRODUCTS
US4423049A (en) 1981-12-28 1983-12-27 Mead Johnson & Company 2-[4-[(4,4-Dialkyl-2,6-piperidinedion-1-yl)butyl]-1-piperazinyl]pyrimidines
DE3321969A1 (en) 1983-06-18 1984-12-20 Troponwerke GmbH & Co KG, 5000 Köln 2-PYRIMIDINYL-1-PIPERAZINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THE SAME
DK169601B1 (en) 1983-10-17 1994-12-19 Duphar Int Res Piperazine derivatives and pharmaceutical preparations containing such derivative, as well as piperazine derivatives with intermediate use
GB2208646B (en) 1987-08-13 1991-06-26 Glaxo Group Ltd Indole derivatives
ATE139230T1 (en) 1988-12-15 1996-06-15 Abbott Lab 5-HT SELECTIVE AGENTS
IL98392A (en) 1990-06-07 1996-01-19 Wellcome Found Indole derivatives their preparation and pharmaceutical compositions containing them
US5545644A (en) 1990-10-15 1996-08-13 Pfizer Inc. Indole derivatives
CZ283018B6 (en) 1991-02-01 1997-12-17 Merck Sharp And Dohme Limited Imidazole, triazole and tetrazole derivatives, process of their preparation, their use and pharmaceuticals based thereon
DE69232003T2 (en) 1991-09-18 2002-04-25 Glaxo Group Ltd Benzanilide derivatives as 5-HT1D antagonists
CA2084531A1 (en) 1991-12-19 1993-06-20 David W. Smith Antimigraine 4-pyrimidinyl and pyridinyl derivatives of indol-3yl-alkyl piperazines
SI9300097B (en) 1992-02-27 2001-12-31 Janssen Pharmaceutica Nv (benzodioxan, benzofuran or benzopyran) alkylamino) alkyl substituted guanidines
US5521188A (en) 1993-09-16 1996-05-28 Bristol-Myers Squibb Company Antimigraine cyclobutenedione derivatives of indolylalkyl-pyridinyl and pyrimidinylpiperazines
US5801170A (en) 1993-12-07 1998-09-01 Smithkline Beecham Plc Heterocyclic biphenylylamides useful as 5HT1D antagonists
SE9504661D0 (en) * 1995-12-22 1995-12-22 Astra Pharma Inc New compounds
US6221868B1 (en) * 1997-06-27 2001-04-24 Nippon Kayaku Kabushiki Kaisha Remedies/preventives for frequent urination/urinary incontinence and tropone derivatives
JP3441636B2 (en) 1997-11-21 2003-09-02 株式会社エヌ・ティ・ティ・ドコモ Apparatus and method for determining channel estimation value, receiving apparatus, and transmission system

Also Published As

Publication number Publication date
DE60130677T2 (en) 2008-07-17
DE60130677D1 (en) 2007-11-08
ES2292636T3 (en) 2008-03-16
US20040067962A1 (en) 2004-04-08
ATE374192T1 (en) 2007-10-15
WO2002044159A2 (en) 2002-06-06
US6864262B2 (en) 2005-03-08
CA2427098A1 (en) 2002-06-06
WO2002044159A3 (en) 2002-08-22
EP1341777A2 (en) 2003-09-10
JP2004517081A (en) 2004-06-10
EP1341777B1 (en) 2007-09-26
WO2002044159A8 (en) 2003-11-20

Similar Documents

Publication Publication Date Title
EP1450808B8 (en) Quinazoline derivatives for the treatment of t cell mediated diseases
GB0111523D0 (en) Chemical compounds
DE60112974D1 (en) Carbolinderivate
AP1699A (en) New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors
NZ545506A (en) Therapeutic agents useful for treating pain
JO2311B1 (en) Alkyne-aryl phosphodiesterase-4 inhibitors
BG108269A (en) Pyrazolopyrimidines as therapeutic agents
SE9903760D0 (en) New compounds
IL144643A0 (en) Jak-3 inhibitors for treating allergic disorders
GB0124933D0 (en) Chemical compounds
MXPA04002167A (en) 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases.
GB0005251D0 (en) Therapeutic compounds
UA74337C2 (en) Use of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine for treating bipolar disorders and mania
MXPA03002911A (en) Chemical compounds.
MXPA03009750A (en) Chemical compounds.
MXPA02012076A (en) Chemical compounds.
AU2001266575A1 (en) Chemical compounds
DE60205899D1 (en) 1-biaryl-1,8-naphthyridin-4-one als phosphodieseterase-inhibitoren
TW200508199A (en) Novel compound
MXPA02012713A (en) A COMBINATION OF FBPase INHIBITORS AND ANTIDIABETIC AGENTS USEFUL FOR THE TREATMENT OF DIABETES.
AU2001263278A1 (en) Cyclic gmp-specific phosphodiesterase inhibitors
WO2004030671A3 (en) Use of 4-amino-quinazolines as anti cancer agents
AU2002230411A1 (en) 1-(2-m-methanesulfonamidophenylethyl)-4-(m-trifluoromethylphenyl)piperazine and pharmaceutically acceptable salts and solvates thereof and their use in the treatment of incontinence
AU2001296699A1 (en) Condensed pyrazindione derivatives as pde inhibitors
GB0202265D0 (en) New therapeutic use